External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>The road construction companies under coverage are anticipated to report flattish revenue as the execution was affected by extreme rainfall.</li><li>EBITDA is expected to decline by 2.5%, while APAT is projected to be 1.5% higher YoY.</li><li>EBITDA margins are estimated at 14.2%, compared to 14.8% in the same period last year. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The road construction companies under coverage are anticipated to report flattish revenue as the execution was affected by extreme rainfall.EBITDA is expected to decline by 2.5%, while APAT is projected to be 1.5% higher YoY.EBITDA margins are estimated at 14.2%, compared to 14.8% in the same period last year. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Aurobindo Pharma: EBITDA (+41% YoY) was in line with our/consensus estimates as 10% sales growth (-3% QoQ US, +8% EU, and +53% YoY in growth markets), higher gross margin (+544 bps YoY), was offset by higher staff (+13%) and SG&amp;A (+22% ex-R&amp;D – remediation cost of USD 9 mn and Pen-G plant opex, R&amp;D was -13% YoY)</li><li>ARBP expects (1) steady growth in the US oral solid, led by new launches and volume gain, (2) specialty/injectable to improve QoQ and it targets reach USD 600 mn sales globally in FY25 (~USD 141 mn in Q1FY25), (3) EU sales at Euro 880-900 mn on new launch visibility, (4) EBITDA margin of 21-22% in FY25 (21.4% in Q1) on reduction in remediation spend and Pen-G plant scale-up led leverage, and (5) tax rate at 27-28% in FY25</li><li>Factoring Q1, we have raised our EPS by 3/2% for FY25/26E and revise the TP to INR 1,520 (20x Q1FY27E from 18x)</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma: EBITDA (+41% YoY) was in line with our/consensus estimates as 10% sales growth (-3% QoQ US, +8% EU, and +53% YoY in growth markets), higher gross margin (+544 bps YoY), was offset by higher staff (+13%) and SG&amp;A (+22% ex-R&amp;D – remediation cost of USD 9 mn and Pen-G plant opex, R&amp;D was -13% YoY)ARBP expects (1) steady growth in the US oral solid, led by new launches and volume gain, (2) specialty/injectable to improve QoQ and it targets reach USD 600 mn sales globally in FY25 (~USD 141 mn in Q1FY25), (3) EU sales at Euro 880-900 mn on new launch visibility, (4) EBITDA margin of 21-22% in FY25 (21.4% in Q1) on reduction in remediation spend and Pen-G plant scale-up led leverage, and (5) tax rate at 27-28% in FY25Factoring Q1, we have raised our EPS by 3/2% for FY25/26E and revise the TP to INR 1,520 (20x Q1FY27E from 18x)Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Aurobindo Pharma, Berger Paints, Metro Brands

HSIE Results Daily: Aurobindo Pharma, Berger Paints, Metro Brands, Aarti Industries

Equity Bottom-Up

<ul><li>Robust &amp; Diversified Order Book: PNCIL has an order book valued at Rs 14,100 Cr (as of 30th June 2024), indicating revenue visibility for the next 2-2.5 years.</li><li>The total value of contracts, including a contract worth Rs 4,994 Cr where the company is L1, exceeds Rs 19,000 Cr, which is over 2.5 times FY24 revenue.</li><li>The order book is well-diversified between roads and water projects..</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Robust &amp; Diversified Order Book: PNCIL has an order book valued at Rs 14,100 Cr (as of 30th June 2024), indicating revenue visibility for the next 2-2.5 years.The total value of contracts, including a contract worth Rs 4,994 Cr where the company is L1, exceeds Rs 19,000 Cr, which is over 2.5 times FY24 revenue.The order book is well-diversified between roads and water projects..Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PNC Infratech Ltd - Project Execution to Pick Up & Margins To Be Maintained.

<ul><li>We anticipate road construction companies under our coverage to report revenue, and APAT growth of 6% and 10%, while EBITDA is expected to be flattish YoY.</li><li>The project execution during the quarter moderated on the back of an election, shortage of labour, and extreme heat conditions.</li><li>We estimate EBITDA margins to be 14.5%, compared to 15.5% YoY. APAT is expected to be higher on account of exceptional gains during the quarter.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We anticipate road construction companies under our coverage to report revenue, and APAT growth of 6% and 10%, while EBITDA is expected to be flattish YoY.The project execution during the quarter moderated on the back of an election, shortage of labour, and extreme heat conditions.We estimate EBITDA margins to be 14.5%, compared to 15.5% YoY. APAT is expected to be higher on account of exceptional gains during the quarter.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India

PNC Infratech Limited operates as an infrastructure construction, development, and management company. The Company constructs highways, bridges, fly-overs, power transmission lines, and airport runways. PNC Infratech also provides construction services for waste management and industrial area development projects.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

PNC Infratech Ltd (PNCL IN)

Q2FY25 Earnings Preview - INFRA-ROAD

The road construction companies under coverage are anticipated to report flattish revenue as the execution was affected by extreme rainfall.

Axis Direct

HSIE Results Daily: Aurobindo Pharma, Berger Paints, Metro Brands

EBITDA (+41% YoY) was in line with our/consensus estimates as 10% sales growth (-3% QoQ US, +8% EU, and +53% YoY in growth markets)

HDFC Securities

HSIE Results Daily: Aurobindo Pharma, Berger Paints, Metro Brands, Aarti Industries

EBITDA (+41% YoY) was in line with our/consensus estimates as 10% sales growth (-3% QoQ US, +8% EU, and +53% YoY in growth markets), higher gross...

HDFC Securities

PNC Infratech Ltd - Project Execution to Pick Up & Margins To Be Maintained.

Robust & Diversified Order Book: PNCIL has an order book valued at Rs 14,100 Cr (as of 30th June 2024), indicating revenue visibility for the next...

Axis Direct

Road Infra- Q1FY25 Result Preview

We estimate EBITDA margins to be 14.5%, compared to 15.5% YoY. APAT is expected to be higher on account of exceptional gains during the quarter.

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)